Do you want to read an article? Please log in or register.
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study
Multiple Sclerosis
Related content
Multiple Sclerosis
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
PLoS One.
Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G
doi: 10.1371/
Multiple Sclerosis
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
J Neurol Neurosurg Psychiatry.
Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H
doi: 10.1136/jnnp-2018-319831.
Multiple Sclerosis
Multiple sclerosis in the real world: A systematic review of fingolimod as a case study
Autoimmun Rev.
Ziemssen T, Medin J, Anne-Marie Couto C, Mitchell CR
doi: 10.1016/j.autrev.2017.02.007.
Multiple Sclerosis
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
Neurol Ther.
Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A
doi: 10.1007/
Multiple Sclerosis
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)
doi: 10.1111/ene.13594.
Multiple Sclerosis
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study
J Neurol.
Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group
doi: 10.1007/s00415-018-9070-x.
Multiple Sclerosis
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
Eur J Neurol.
Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL
doi: 10.1111/ene.13272.
RECOMMENDED
Multiple Sclerosis
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study
Neurology.
Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Góra MK, Illes Z, Kant M, Mezei Z, Petersen T, Rasmussen PV, Roshanisefat H, Hassanpour-Kalam-Roudy H, Sejbæk T, Tsakiri A, Weglewski A, Sorensen PS, Magyari M
doi: 10.1212/WNL.
RECOMMENDED
Multiple Sclerosis
Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Neurol Neuroimmunol Neuroinflamm.
Diem L, Daponte A, Findling O, Miclea A, Briner M, Salmen A, Gold R, Kilidireas C, Chan A, Evangelopoulos ME, Hoepner R
doi: 10.1212/NXI.0000000000000660.